The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients
dc.contributor.buuauthor | Ersoy, Canan | |
dc.contributor.buuauthor | Kıyıcı, Sinem Kucuksaraç | |
dc.contributor.buuauthor | Budak, Ferah Ah | |
dc.contributor.buuauthor | Oral, Haluk Barbaros | |
dc.contributor.buuauthor | Güçlü, Metin | |
dc.contributor.buuauthor | Duran, Cevdet | |
dc.contributor.buuauthor | Selimoǧlu, Hadi | |
dc.contributor.buuauthor | Ertürk, Erdinç | |
dc.contributor.buuauthor | Tuncel, Ercan | |
dc.contributor.buuauthor | İmamoğlu, Şazi | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji Anabilim Dalı Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0003-0463-6818 | tr_TR |
dc.contributor.researcherid | K-7285-2012 | tr_TR |
dc.contributor.researcherid | ABI-4847-2020 | tr_TR |
dc.contributor.researcherid | F-4657-2014 | tr_TR |
dc.contributor.researcherid | AAH-8861-2021 | tr_TR |
dc.contributor.researcherid | AAJ-6536-2021 | tr_TR |
dc.contributor.scopusid | 6701485882 | tr_TR |
dc.contributor.scopusid | 12753880400 | tr_TR |
dc.contributor.scopusid | 6701913697 | tr_TR |
dc.contributor.scopusid | 7004498001 | tr_TR |
dc.contributor.scopusid | 15073842600 | tr_TR |
dc.contributor.scopusid | 12754039000 | tr_TR |
dc.contributor.scopusid | 15074185600 | tr_TR |
dc.contributor.scopusid | 7005488796 | tr_TR |
dc.contributor.scopusid | 7006929833 | tr_TR |
dc.contributor.scopusid | 6602297533 | tr_TR |
dc.date.accessioned | 2024-02-26T11:24:39Z | |
dc.date.available | 2024-02-26T11:24:39Z | |
dc.date.issued | 2008-07 | |
dc.description.abstract | The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT) + regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5 +/- 1.5 years, diabetes duration of 17.9 +/- 6.3 months and body mass index (BMI) of 31.7 +/- 0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT + REP. In the following 12 weeks, metformin (mean daily dosage of 1381 +/- 85 mg) was added. After the first period with MNT + REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial. plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in P cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT + REP, independent from its' favourable effects on BMI and glycemic control. | en_US |
dc.identifier.citation | Ersoy, C. vd. (2008)" The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients". Diabetes Research and Clinical Practice, 81(1), 56-60. | en_US |
dc.identifier.endpage | 60 | tr_TR |
dc.identifier.issn | 0168-8227 | |
dc.identifier.issn | 1872-8227 | |
dc.identifier.issue | 1 | tr_TR |
dc.identifier.pubmed | 18358555 | tr_TR |
dc.identifier.scopus | 2-s2.0-44649103918 | tr_TR |
dc.identifier.startpage | 56 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/j.diabres.2008.02.006 | en_US |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168822708000879 | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/39968 | en_US |
dc.identifier.volume | 81 | tr_TR |
dc.identifier.wos | 000257567000010 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | Diabetes Research and Clinical Practice | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Metformin | en_US |
dc.subject | Obesity | en_US |
dc.subject | PAI-1 | en_US |
dc.subject | Type 2 diabetes mellitus | en_US |
dc.subject | Endocrinology & Metabolism | en_US |
dc.subject | VEGF | en_US |
dc.subject | Endothelial growth-factor | en_US |
dc.subject | C-reactive protein | en_US |
dc.subject | Plasminogen-activator inhibitor-1 | en_US |
dc.subject | Cardiovascular risk-factors | en_US |
dc.subject | Glucagon-like peptide-1 | en_US |
dc.subject | Insulin resistance | en_US |
dc.subject | Circulating levels | en_US |
dc.subject | Term treatment | en_US |
dc.subject | Mellitus | en_US |
dc.subject | Markers | en_US |
dc.subject.emtree | Glifor | en_US |
dc.subject.emtree | Glucose | en_US |
dc.subject.emtree | Hemoglobin A1c | en_US |
dc.subject.emtree | High density lipoprotein cholesterol | en_US |
dc.subject.emtree | Metformin | en_US |
dc.subject.emtree | Plasminogen activator inhibitor 1 | en_US |
dc.subject.emtree | Vasculotropin | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Blood pressure | en_US |
dc.subject.emtree | Body fat | en_US |
dc.subject.emtree | Body mass | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Diabetic patient | en_US |
dc.subject.emtree | Diet restriction | en_US |
dc.subject.emtree | Disease duration | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Glucose blood level | en_US |
dc.subject.emtree | Glycemic control | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Non insulin dependent diabetes mellitus | en_US |
dc.subject.emtree | Obesity | en_US |
dc.subject.emtree | Pancreas islet beta cell | en_US |
dc.subject.emtree | Postprandial state | en_US |
dc.subject.emtree | Thrombosis | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Vascular endothelium | en_US |
dc.subject.emtree | Vasculitis | en_US |
dc.subject.emtree | Waist circumference | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Blood glucose | en_US |
dc.subject.mesh | Body mass index | en_US |
dc.subject.mesh | Diabetes mellitus, type 2 | en_US |
dc.subject.mesh | Exercise | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Hypoglycemic agents | en_US |
dc.subject.mesh | Lipids | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Matrix metalloproteinase 9 | en_US |
dc.subject.mesh | Metformin | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Obesity | en_US |
dc.subject.mesh | Plasminogen activator inhibitor 1 | en_US |
dc.subject.mesh | Prospective studies | en_US |
dc.subject.mesh | Vascular endothelial growth factor a | en_US |
dc.subject.mesh | Waist-hip ratio | en_US |
dc.subject.scopus | Diabetes Mellitus; Biguanide Derivative; Cancer Risk | en_US |
dc.subject.wos | Endocrinology & metabolism | en_US |
dc.title | The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q4 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: